Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (DE:38I)
FRANKFURT:38I
Earnings Data
Report Date
Feb 19, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.86Last Year’s EPS
-1.1Same Quarter Last Year
Moderate Buy
Based on 22 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Negative
The earnings call presented a mix of progress and challenges. While significant advancements were made in the lonvo-z program and financial stability was maintained, the clinical hold on nex-z trials due to patient safety concerns significantly impacted the company's outlook. The sentiment is largely influenced by the serious nature of the clinical hold and patient safety issues.Company Guidance
Lonvo-z Phase III Clinical Trial Progress
Enrollment for the HAELO Phase III clinical trial for HAE was completed in September 2025, putting Intellia on track to share top line data by mid-2026, submit a BLA in the second half of 2026, and anticipate commercial launch in the U.S. in the first half of 2027.
Financial Position and Extended Cash Runway
Intellia Therapeutics maintains a solid balance sheet with cash, cash equivalents, and marketable securities at $669.9 million as of September 30, 2025. Through restructuring and ATM facility, cash runway extended into mid-2027, aligning with lonvo-z's anticipated U.S. commercial launch.
Increased Collaboration Revenue
Intellia's collaboration revenue increased to $13.8 million during the third quarter of 2025, up from $9.1 million in the prior year quarter, primarily driven by cost reimbursements from Regeneron Pharmaceuticals.
DE:38I Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:38I Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 07, 2025 | €9.73 | €10.20 | +4.82% |
May 08, 2025 | €6.35 | €7.35 | +15.78% |
Feb 27, 2025 | €10.57 | €11.21 | +6.05% |
Nov 07, 2024 | €14.63 | €15.36 | +4.99% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Intellia Therapeutics (DE:38I) report earnings?
Intellia Therapeutics (DE:38I) is schdueled to report earning on Feb 19, 2026, TBA (Confirmed).
What is Intellia Therapeutics (DE:38I) earnings time?
Intellia Therapeutics (DE:38I) earnings time is at Feb 19, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Intellia Therapeutics stock?
The P/E ratio of Intellia Therapeutics is N/A.
What is DE:38I EPS forecast?
DE:38I EPS forecast for the fiscal quarter 2025 (Q4) is -0.86.